APA (7th ed.) Citation

Y, X., Y, L., Z, C., C, S., X, Z., Y, L., . . . C, L. (2026). GBVAM as a Novel NHE1 Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity via PI3K/Akt/mTOR Pathway. Drug design, development and therapy, 20, 585989. https://doi.org/10.2147/DDDT.S585989

Chicago Style (17th ed.) Citation

Y, Xu, Li Y, Cheng Z, Shao C, Zhao X, Liu Y, Gou X, and Li C. "GBVAM as a Novel NHE1 Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity via PI3K/Akt/mTOR Pathway." Drug Design, Development and Therapy 20 (2026): 585989. https://doi.org/10.2147/DDDT.S585989.

MLA (9th ed.) Citation

Y, Xu, et al. "GBVAM as a Novel NHE1 Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity via PI3K/Akt/mTOR Pathway." Drug Design, Development and Therapy, vol. 20, 2026, p. 585989, https://doi.org/10.2147/DDDT.S585989.